The invention discloses a set of genes used for
bladder cancer detection and application. The set of genes used for
bladder cancer detection comprise the following 32 genes: a CA9
gene, a CDK1
gene, aCTSE
gene, a DMBT1 gene, an
ERBB2 gene, an HOXA13 gene, an IGF2 gene, a CXCR2 gene, an MAGEA3 gene, an MDK gene, an MMP1 gene, an MMP12 gene, a RBP2 gene, a CCL18 gene, an SNAI2 gene, a VEGFA gene, an MFAP5 gene, an SGK2 gene, a WFDC2 gene, a POSTN gene, an NPFFR2 gene, an ANXA10 gene, a CTAG2 gene, a ZDHHC2 gene, a KRT20 gene, a PPP1R14D gene, an FGD3 gene, an AHNAK2 gene, an SEMA3D gene, a ZNF707 gene, a LOC100652931 gene and an LINC00565 gene. High accuracy and objective result interpretation by adopting a detection kit of the set of genes for
bladder cancer detection are proven clinically; meanwhile, as non-invasive detection, compared with existing cystoscopy, the detection kit has the
advantage that the compliance of a patient is greatly improved, and the detection kit has importantclinical significance to
early detection and postoperation monitoring of bladder
cancer.